Vimarsana
Biggest News Aggregation in the World

Page 2 - Efficacy Endpoint News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Stay updated with breaking news from Efficacy Endpoint. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Top News In Efficacy Endpoint Today - Breaking & Trending Today

Jazz Pharmaceuticals Announces First Patient Enrolled in Phase 2b Clinical Trial Evaluating Novel Suvecaltamide (JZP385) for Once-Daily Treatment of Adults with Essential Tremor - Vimarsana News

Jazz Pharmaceuticals Announces First Patient Enrolled in Phase 2b Clinical Trial Evaluating Novel Suvecaltamide (JZP385) for Once-Daily Treatment of Adults with Essential Tremor

Published: December 15, 2021

/PRNewswire/ -- Jazz Pharmaceuticals plc (Nasdaq: JAZZ) today announced that the first patient has been enrolled in a global Phase 2b clinical trial evaluating...

Source: prnewswire.com
Related Topics:
United StatesUnited KingdomMarka GoldsteinKristin BhavnaniPatrick MccartneyAndrean FlynnRob IannoneJazz Pharmaceuticals IncCommission File NoMovement Disorder SocietyJazz PharmaceuticalsInternational Essential Tremor FoundationHead Of Global Corporate CommunicationsExchange CommissionJazz Pharmaceuticals Announces Acquisition Of Cavion IncResearch InstituteEuropean UnionInternational ParkinsonAkrimax PharmaceuticalsNational Institute Of Neurological DisordersInternational Essential TremorConsensus StatementTask ForceMovement DisorderDaily Living
Jazz Pharmaceuticals plc: Jazz Pharmaceuticals Announces First Patient Enrolled in Phase 2b Clinical Trial Evaluating Novel Suvecaltamide (JZP385) for Once-Daily Treatment of Adults with Essential Tremor - Vimarsana News

Jazz Pharmaceuticals plc: Jazz Pharmaceuticals Announces First Patient Enrolled in Phase 2b Clinical Trial Evaluating Novel Suvecaltamide (JZP385) for Once-Daily Treatment of Adults with Essential Tremor

Published: December 15, 2021

DUBLIN, Dec. 15, 2021 /PRNewswire/ -- Jazz Pharmaceuticals plc (Nasdaq: JAZZ) today announced that the first patient has been enrolled in a global Phase 2b clinical trial evaluating the safety

Source: finanznachrichten.de
Related Topics:
United StatesUnited KingdomMarka GoldsteinKristin BhavnaniPatrick MccartneyAndrean FlynnRob IannoneJazz Pharmaceuticals IncCommission File NoMovement Disorder SocietyJazz PharmaceuticalsInternational Essential Tremor FoundationJazz Pharmaceuticals Announces Acquisition Of Cavion IncPrnewswire Jazz PharmaceuticalsEuropean UnionAkrimax PharmaceuticalsNational Institute Of Neurological DisordersHead Of Global Corporate CommunicationsExchange CommissionResearch InstituteInternational ParkinsonInternational Essential TremorConsensus StatementTask ForceMovement Disorder